NKCFO LLC’s Exagen XGN Stock Holding History

NKCFO LLC’s Portfolio XGN Stock Details XGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-40,000	Closed	-$440K	–	123
2025 Q3	$440K	Buy	+40,000	New	+$354K	0.13%	64

Other funds holding XGN

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SAM

Silvercrest Asset Management New York $13.8B AUM 28.39% 1-Year Est. Return

KCM

Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return

Wexford Capital West Palm Beach, Florida $690M AUM 57.92% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

MBAM

Mink Brook Asset Management West Palm Beach, Florida $179M AUM 37.68% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

NKCFO LLC's XGN Position: Q4 2025 in Review

NKCFO LLC sold out of Exagen (XGN) in Q4 2025, closing a stake of 40,000 shares — an estimated $440K sold.

NKCFO LLC first reported a position in XGN in Q3 2025 and held it in 1 quarter. The position peaked at $440K in Q3 2025. 80 funds tracked by Wall St. Rank hold XGN as of Q4 2025.

NKCFO LLC reported no remaining Exagen position as of Q4 2025 after selling out during the quarter.
NKCFO LLC sold 40,000 Exagen shares in Q4 2025, an estimated $440K.
NKCFO LLC first reported a position in Exagen in Q3 2025 and held it in 1 quarter.
NKCFO LLC's Exagen position peaked at $440K in Q3 2025.
80 funds tracked by Wall St. Rank held Exagen as of Q4 2025.

Based on NKCFO LLC's 13F filing for Q4 2025, filed 2 Feb 2026.